首页> 外文OA文献 >Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)

【2h】

Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)

机译：Bevacizumab联合铂 - 紫杉烷化学疗法作为晚期卵巢癌的一线治疗：日本患者安全性和疗效的前瞻性观察研究（JGOG3022试验）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Shinichi Komiyama; Kazuyoshi Kato; Yuki Inokuchi; Hirokuni Takano; Takashi Matsumoto; Atsushi Hongo; Mikiko Asai-Sato; Atsushi Arakawa; Shoji Kamiura; Tsutomu Tabata; Nobuhiro Takeshima; Toru Sugiyama;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial) [J] . Komiyama Shinichi, Kato Kazuyoshi, Inokuchi Yuki, International journal of clinical oncology . 2019,第1期

机译：Bevacizumab结合铂 - 紫杉烷化疗作为晚期卵巢癌的一线治疗：日本患者安全性和疗效的前瞻性观察研究（JGOG3022试验）
2. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [J] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, BMC Cancer . 2018,第1期

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法
3. AvaALL: Open-Label Randomized Phase 1Mb Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Continuous Bevacizumab (BV) Treatment Beyond Disease Progression in Patients (pts) With Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) After First-Line (1L) Treatment With BV Plus Platinum-Doublet Chemotherapy (CT) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla11期

机译：AvaALL：开放标签随机1Mb临床试验，评估在初次手术后晚期非鳞状非小细胞肺癌（NSCLC）患者病情进展之外，是否进行持续贝伐单抗（BV）治疗的标准治疗的有效性和安全性BV加上铂金双线化疗（CT）的线（1L）治疗
4. Applying Quantitative Adiposity Feature Analysis Models to Predict Benefit of Bevacizumab-based Chemotherapy in Ovarian Cancer Patients [C] . Yunzhi Wang, Yuchen Qiu, Theresa Thai, Conference on medical imaging . 2016

机译：应用定量肥胖特征分析模型预测基于贝伐单抗的卵巢癌化疗获益
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial) [O] . Shinichi Komiyama, Kazuyoshi Kato, Yuki Inokuchi, -1

机译：贝伐单抗联合铂-紫杉烷化疗作为晚期卵巢癌的一线治疗：对日本患者安全性和有效性的前瞻性观察研究（JGOG3022试验）
7. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [O] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, 2018

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法

Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)

著录项

引文网络

相似文献

相关主题

期刊订阅